31 March 2026

GenIP Plc

("GenIP" or the "Company")

Commercial Update, Pipeline Development & Strategic Progress

GenIP Plc, the technology evaluation and commercialisation platform, provides a commercial update on pipeline development, product expansion, and commercial resourcing as the Company continues to scale rapidly in early 2026, eighteen months after IPO.

Commercial Highlights:

·    Following FY25 revenue growth of c.330%, the Company continues to receive new orders across the US, Asia and other key markets.

·    Renewal discussions with multiple FY25 clients are progressing well, with several expanding their scope of work, consistent with GenIP's historically strong 90% client retention.

·    Asia has become GenIP's largest market, growing c.3,500% year on year. Europe and Latin America delivered growth of c.111% and c.51%, respectively.

·    Client demand is shifting toward multi-year, portfolio-level engagements, increasing engagement size and depth.

·    Invention Prioritizer and Invention Validator continue to gain traction, broadening the product suite and increasing revenue per client.

·    Commercial leadership strengthened with new enterprise and regional appointments to support pipeline expansion.

Pipeline Development & Regional Momentum

GenIP's commercial pipeline continues to expand, with multi-institution opportunities at advanced stages across Asia, Europe, the Middle East and Latin America. Engagement sizes are increasing as clients seek broader portfolio-level insights in addition to single-technology evaluations.

Regional growth in FY25 was driven by:

·      Asia: (c.3,500%) - now GenIP's largest market

·      Europe: (c.111%) - accelerating from a low base

·      Latin America: (c.51%) - strong long-term potential supported by deep institutional connectivity

·      Rest of World: (c.21%)

The breadth of the pipeline provides increasing visibility into multi-year commercial opportunities.

Product Expansion & Client-Led Development

GenIP's product suite continues to broaden:

Invention Prioritizer - developed in FY25 through work with a leading research university in Saudi Arabia, is now in active use by multiple clients, including by CNEN (Brazil's National Nuclear Energy Commission).

Invention Validator - progressing through its first deployment at a leading South African research university with additional client discussions underway. The product carries an expected 60% gross margin and complements GenIP's broader portfolio-support strategy.

Product development remains client-led, ensuring strong market fit and alignment with evolving customer needs.

Commercial Resourcing

To support the next phase of growth, GenIP has strengthened its commercial leadership:

Global Enterprise and Corporate Sales Lead - A senior commercial leader has joined to develop and expand GenIP's previously untapped corporate and enterprise market on a global scale. This role aligns directly with the Company's strategy to increase its corporate client base and diversify revenue beyond its established academic foundation.

Latin America Commercial Lead - A regional specialist with deep institutional connectivity, including an advisory role with the World Intellectual Property Organization (WIPO), has been appointed to accelerate regional growth.

Asia Sales Resource - An additional sales resource is being recruited to support the Company's fastest-growing market.

These appointments enhance GenIP's ability to scale across high growth regions and support the expanding pipeline.

Outlook and Near-Term Catalysts

GenIP continues to make strong progress against its commercial priorities. The Company is expanding its global footprint, deepening client relationships and broadening its product suite.

Near-term commercial catalysts include:

·    Progression of multiple advanced-stage institutional opportunities across Asia, Europe and Latin America.

·    Expansion of existing FY25 client engagements into multi-year, portfolio-level programmes.

·    Additional deployments of Invention Prioritizer and Invention Validator.

·    Strengthening the corporate pipeline under new enterprise sales leadership.

·    Completion of new commercial hires in Asia to support demand in the Company's largest market.

With rising demand, increasing engagement size and a growing corporate pipeline, GenIP is well positioned for continued commercial progress in 2026.

Melissa Cruz, Chief Executive Officer, commented:

"GenIP is delivering strong progress across all of our strategic priorities. Asia's exceptional growth, Europe's accelerating momentum and the long-term potential we see in Latin America demonstrate the global demand for our platform and products.

Clients are deepening their engagement with us, adopting our broader product suite and increasingly seeking portfolio-level insight. With a growing pipeline, strong renewal activity and a clear strategic focus, GenIP is well positioned for its next phase of growth."

For further information regarding GenIP, please visit www.genip.ai, or contact:

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

Notes to Editors

About GenIP

GenIP is a next-generation consultancy at the intersection of generative AI and innovation strategy. We empower corporates, venture funds, and research institutions to evaluate, commercialise, and scale breakthrough technologies. By combining proprietary GenAI algorithms with expert human analysis, GenIP delivers decision-grade insights and talent solutions that accelerate innovation outcomes.

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and execution.

Vision & Strategy

GenIP aims to become the global leader in generative AI analytics for innovation commercialisation. Our strategy is anchored in three growth pillars:

●    Organic Expansion
Scale Invention Evaluator and Recruitment Services through targeted outreach to corporates, VCs, and research institutions, supported by strategic marketing and digital engagement.

●    Service Deepening
Enhance functionality and margin by expanding GenAI capabilities within both service lines-unlocking new use cases and customer segments.

●    Strategic Acquisitions
Pursue bolt-on acquisitions of complementary GenAI services with validated market traction to broaden our offering and accelerate growth.

Forward looking statements

Certain statements contained in this announcement constitute forward-looking statements. When used in this announcement, the words "may", "would", "could", "will", "intend", "plan", "anticipate", "believe", "seek", "propose", "estimate", "expect", and similar expressions, as they relate to the Company, are intended to identify forward-looking statements. These statements include, but are not limited to, statements regarding intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial position, liquidity, prospects, growth, strategies and expectations of the industry in which the Company operates.

Such statements reflect the Company's current views with respect to future events and are subject to certain risks, uncertainties and assumptions. Many factors could cause the Company's actual results, performance or achievements to materially differ from those described in this announcement Should one or more of these risks or uncertainties materialise, or should assumptions underlying forward-looking statements prove incorrect, actual results may differ materially from those described in this announcement as "intended", "planned", "anticipated", "believed", "proposed", "estimated" or "expected".

For the avoidance of doubt, the contents of the Company's website and any hyperlinks accessible from the Company's website are not incorporated by reference into, and do not form part of, this announcement and investors should not rely on them.

-ENDS-